

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

YPOZANE 1.875 mg tablets for dogs

YPOZANE 3.75 mg tablets for dogs

YPOZANE 7.5 mg tablets for dogs

YPOZANE 15 mg tablets for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:

Each tablet contains 1.875 mg, 3.75 mg, 7.5 mg or 15 mg osaterone acetate.

Excipients:

Qualitative composition of excipients and other constituents
Lactose monohydrate
Pregelatinised starch
Carmellose calcium
Maize starch
Talc
Magnesium stearate

Round, white, biconvex tablet of 5.5 mm, 7 mm, 9 mm or 12 mm diameter.

3. CLINICAL INFORMATION

3.1 Target species

Dogs (male).

3.2 Indications for use for each target species

Treatment of benign prostatic hypertrophy (BPH) in male dogs.

3.3 Contraindications

None.

3.4 Special warnings

In dogs with BPH associated with prostatitis, the product can be administered concurrently with antimicrobials.

3.5 Special precautions for use

Special precautions for safe use in the target species:

A transient reduction of plasma cortisol concentration may occur; this may continue for several weeks after administration. Appropriate monitoring should be implemented in dogs under stress (e.g. post-operative) or those with hypoadrenocorticism. The response to an ACTH stimulation test may also be suppressed for several weeks after administration of osaterone.

Use with caution in dogs with a history of liver disease, as safety of use of the product in these dogs has not been thoroughly investigated, and as treatment of some dogs with liver disease has resulted in reversible elevation of ALT and ALP in clinical trials.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

A single oral dose of 40 mg osaterone acetate in human males was followed by a sporadic decrease in FSH, LH and testosterone, reversible after 16 days. There was no clinical effect.

In female laboratory animals, osaterone acetate caused serious adverse effects on reproductive functions. Therefore, women of child-bearing age should avoid contact with, or wear disposable gloves, when administering the product.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs (male):

Very common (>1 animal / 10 animals treated):	Increased appetite ¹ Hypocortisolaemia ¹
Common (1 to 10 animals / 100 animals treated):	Behavioural disorders (e.g., hyperactivity, decreased activity or more social behaviour) ¹
Uncommon (1 to 10 animals / 1,000 animals treated):	Vomiting and/or diarrhoea ¹ Polydipsia ¹ , lethargy ¹ Polyuria ¹ Mammary hyperplasia
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Decreased appetite ¹ Galactorrhoea ² Changes in hair coat (e.g., hair loss or hair modification) ¹

¹ Transient.

² Associated with mammary hyperplasia.

In clinical trials, treatment with the veterinary medicinal product was not discontinued and all dogs recovered without any specific therapy.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Not applicable.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

3.9 Administration routes and dosage

For oral use.

Administer 0.25 – 0.5 mg osaterone acetate per kilogram bodyweight, once a day, for 7 days as follows:

Dog's weight	Strength of tablet to be administered	Number of tablets per day	Treatment duration
3 to 7.5 kg*	1.875 mg tablet	1 tablet	7 days
7.5 to 15 kg	3.75 mg tablet		
15 to 30 kg	7.5 mg tablet		
30 to 60 kg	15 mg tablet		

*No data are available for dogs less than 3 kg bodyweight

Tablets can be given either directly into the mouth or with food. The maximum dose should not be exceeded.

The onset of clinical response to treatment is usually seen within 2 weeks. The clinical response persists for at least 5 months after treatment.

Re-evaluation by the veterinarian should take place 5 months after treatment or earlier if clinical signs recur. A decision to retreat at this or at a later time point should be based on veterinary examination taking into account the risk benefit profile of the product. If clinical response to treatment is considerably shorter than expected, a re-evaluation of the diagnosis is necessary.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

An overdose study (up to 1.25 mg/kg bodyweight for 10 days, repeated one month later) did not show undesirable effects except for a decrease of cortisol plasma concentration.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QG04C X

4.2 Pharmacodynamics

Benign prostatic hypertrophy (BPH) is a natural consequence of ageing. Over 80% of male dogs above 5 years of age are affected. BPH is a development and enlargement of the prostate due to the male hormone testosterone. This might lead to multiple non-specific clinical signs such as abdominal pain, difficulties in defaecation and urination, blood in urine and locomotive disorders.

Osaterone is a steroid anti-androgen, which inhibits the effects of an excess production of male hormone (testosterone).

Osaterone acetate is a steroid chemically related to progesterone, and as such it has potent progestagen and potent anti-androgen activity. Also, the major metabolite of osaterone acetate (15 β -hydroxylated - osaterone acetate) has anti-androgenic activity. Osaterone acetate inhibits the effects of an excess of male hormone (testosterone) through various mechanisms. It competitively prevents the binding of androgens to their prostatic receptors and blocks the transport of testosterone into the prostate.

No adverse effects on semen quality have been observed.

4.3 Pharmacokinetics

After oral administration with food in dogs, osaterone acetate is rapidly absorbed (T_{max} about 2 hours) and undergoes a first-pass effect mainly in the liver. After a dose of 0.25 mg/kg/day, the mean maximum concentration (C_{max}) in plasma is about 60 μ g/l.

Osaterone acetate is converted to its main, 15 β -hydroxylated metabolite, which is also pharmacologically active. Osaterone acetate and its metabolite are bound to plasma proteins (around 90% and 80% respectively), mainly to albumin. This binding is reversible and not affected by other substances known to specifically bind to albumin.

Osaterone is eliminated within 14 days, mainly in faeces via biliary excretion (60%) and to a lesser extent (25%) in urine. Elimination is slow with a mean half-life ($T_{1/2}$) of about 80 hours. After repeated administration of osaterone acetate at 0.25 mg/kg/day for 7 days, the factor of accumulation is about 3-4 without change in the rates of absorption or elimination. Fifteen days after the last administration, the mean plasma concentration is about 6.5 μ g/l.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Carton box containing one aluminium/aluminium blister with 7 tablets.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/06/068/001

EU/2/06/068/002

EU/2/06/068/003

EU/2/06/068/004

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 11/01/2007

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE**BOX - 1.875 mg****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane 1.875 mg tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains 1.875 mg osaterone acetate.

3. PACKAGE SIZE

7 tablets.

4. TARGET SPECIES

Dogs (male).

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Oral use.

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/06/068/001

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

BLISTER - 1.875 mg

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
--

Ypozane

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1.875 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE**BOX - 3.75 mg****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane 3.75 mg tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains 3.75 mg osaterone acetate

3. PACKAGE SIZE

7 tablets.

4. TARGET SPECIES

Dogs (male).

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Oral use.

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/06/068/002

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

BLISTER - 3.75 mg

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
--

Ypozane

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

3.75 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE**BOX - 7.5 mg****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane 7.5 mg tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains 7.5 mg osaterone acetate

3. PACKAGE SIZE

7 tablets.

4. TARGET SPECIES

Dogs (male).

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Oral use.

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS**10 THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/06/068/003

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

BLISTER - 7.5 mg

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
--

Ypozane

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

7.5 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

BOX - 15 mg

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ypozane 15 mg tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains 15 mg osaterone acetate

3. PACKAGE SIZE

7 tablets.

4. TARGET SPECIES

Dogs (male).

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/06/068/004

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

BLISTER - 15 mg

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
--

Ypozane

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

15 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

YPOZANE 1.875 mg tablets for dogs
YPOZANE 3.75 mg tablets for dogs
YPOZANE 7.5 mg tablets for dogs
YPOZANE 15 mg tablets for dogs

2. Composition

Each tablet contains 1.875 mg, 3.75 mg, 7.5 mg or 15 mg osaterone acetate

Round, white, biconvex tablet of 5.5 mm, 7 mm, 9 mm or 12 mm diameter.

3. Target species

Dogs (male).

4. Indications for use

Treatment of benign prostatic hypertrophy in male dogs.

5. Contraindications

None.

6. Special warnings

Special warnings:

In dogs with BPH associated with prostatitis, the product can be administered concurrently with antimicrobials.

Special precautions for safe use in the target species:

A transient reduction of plasma cortisol concentration may occur; this may continue for several weeks after administration. Appropriate monitoring should be implemented in dogs under stress (e.g. post-operative) or those with hypoadrenocorticism. The response to an ACTH stimulation test may also be suppressed for several weeks after administration of osaterone.

Use with caution in dogs with a history of liver disease, as safety of use of the product in these dogs has not been thoroughly investigated, and as treatment of some dogs with liver disease has resulted in reversible elevation of ALT and ALP in clinical trials.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

A single oral dose of 40 mg osaterone acetate in human males was followed by a sporadic decrease of sexual hormones, reversible after 16 days. There was no clinical effect.

In female laboratory animals, osaterone acetate caused serious adverse effects on reproductive functions. Therefore, women of child bearing age should avoid contact with, or wear disposable gloves, when administering the product.

Overdose:

An overdose study (up to 1.25 mg/kg bodyweight for 10 days, repeated one month later) did not show undesirable effects except for a decrease of cortisol plasma concentration.

7. Adverse events

Dogs (male):

Very common (> 1 animal / 10 animals treated):
Increased appetite ¹ Hypocortisolaemia (reduction in plasma cortisol) ¹
Common (1 to 10 animals / 100 animals treated):
Behavioural disorders (e.g., hyperactivity, decreased activity or more social behaviour) ¹
Uncommon (1 to 10 animals / 1,000 animals treated):
Vomiting and/or diarrhoea ¹ Polydipsia (increased thirst) ¹ , lethargy ¹ Polyuria (increased urination) ¹ Mammary hyperplasia (mammary enlargement)
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Decreased appetite ¹ Galactorrhoea (lactation) ² Changes in hair coat (e.g., hair loss or hair modification) ¹

¹Transient.

² Associated with mammary hyperplasia.

In clinical trials, treatment with the veterinary medicinal product was not discontinued and all dogs recovered without any specific therapy.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

For oral use.

Administer 0.25 – 0.5 mg osaterone acetate per kilogram bodyweight, once a day, for 7 days as follows:

Dog's weight	Strength of tablet to be administered	Number of tablet per day	Treatment duration
3 to 7.5 kg	1.875 mg tablet	1 tablet	7 days
7.5 to 15 kg	3.75 mg tablet		
15 to 30 kg	7.5 mg tablet		
30 – 60 kg	15 mg tablet		

9. Advice on correct administration

Tablets can be given either directly into the mouth or with food. The onset of clinical response to treatment is usually seen within 2 weeks and persists for at least 5 months after treatment.

Re-evaluation by the veterinarian should take place 5 months after treatment, or earlier if clinical signs recur. A decision to retreat at this or at a later time point should be based on veterinary examination taking into account the risk benefit profile of the medicine.

If clinical response to treatment is considerably shorter than expected, a re-evaluation of the diagnosis is necessary.

The maximum dose should not be exceeded.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the blister after Exp.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/06/068/001-004

Carton box containing one aluminium/aluminium blister with 7 tablets.

15. Date on which the package leaflet was last revised

{MM/YYYY}

Detailed information on this veterinary medicinal product is available Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:

VIRBAC
1^{ère} avenue 2065m LID
06516 Carros
France

Local representatives and contact details to report suspected adverse reactions:

België/Belgique/Belgien
VIRBAC BELGIUM NV
Esperantolaan 4
BE-3001 Leuven
Tél/Tel : +32-(0)16 387 260
phv@virbac.be

Luxembourg/Luxemburg
VIRBAC BELGIUM NV
Esperantolaan 4
BE-3001 Leuven
Belgique / Belgien
Tél/Tel: +32-(0)16 387 260
info@virbac.be

Česká republika
VIRBAC Czech Republic, s.r.o.
Žitavského 496
156 00 Praha 5
Česká republika
Tel.: +420 608 836 529

Magyarország
VIRBAC HUNGARY KFT
Dózsa György út 84. B épület
HU-1068 Budapest
Tel: +36703387177
akos.csoman@virbac.hu

Danmark
VIRBAC Danmark A/S
Profilvej 1
DK-6000 Kolding
Tlf: +45 75521244
virbac@virbac.dk

Malta
VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Franza
Tel: +33 (0) 4 92 08 73 00

Deutschland
VIRBAC Tierarzneimittel GmbH
Rögen 20

Nederland
VIRBAC NEDERLAND BV
Hermesweg 15

DE-23843 Bad Oldesloe
Tel: 49 (4531) 805 111

Eesti

OÜ ZOOVETVARU
Uusaru 5
EE-76505 Saue/Harjumaa
Eesti
Tel: + 372 56480207
pv@zoovet.eu

Ελλάδα

VIRBAC ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.
13^ο χλμ Ε.Ο. Αθηνών - Λαμίας
EL-14452, Μεταμόρφωση
Τηλ: +30 210 6219520
info@virbac.gr

España

VIRBAC ESPAÑA, S.A.
Angel Guimerá 179-181
ES-08950 - Esplugues de Llobregat
(Barcelona)
Tel: + 34 (0) 93 470 79 40

France

VIRBAC France
13^{ème} rue LID
FR-06517 Carros
Tél : +33 800 73 09 10

Ireland

VIRBAC IRELAND
McInerney & Saunders
38, Main Street
Swords, Co Dublin
K67E0A2
Republic Of Ireland
Tel: +44 (0)-1359 243243

Ísland

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Frakkland
Simi: 33 (0) 4 92 08 73 00

Italia

VIRBAC SRL
Via Ettore Bugatti, 15
IT-20142 Milano
Tel: +39 02 40 92 47 1

3771 ND-Barneveld
Tel: +31 (0) 342 427 127
phv@virbac.nl

Norge

VIRBAC Danmark A/S
Profilvej 1
DK-6000 Kolding
Danmark
Tlf: + 45 75521244
virbac@virbac.dk

Österreich

VIRBAC Österreich GmbH
Hildebrandgasse 27
A-1180 Wien
Tel: +43 (0) 1 21 834 260

Polska

VIRBAC Sp.z o.o.
ul. Puławska 314
PL 02-819 Warszawa
Tel.: + 48 22 855 40 46

Portugal

VIRBAC DE Portugal LABORATÓRIOS LDA
Rua do Centro Empresarial
Edif13-Piso 1- Escrit.3
Quinta da Beloura
PT-2710-693 Sintra (Portugal)
Tel: 00 351 219 245 020

Slovenija

MEDICAL INTERTRADE d.o.o.
Brodišče 12,
1236 Trzin
Slovenija
Tel: + 386 1 2529 113
farmakovigilanca@medical-intertrade.si

Slovenská republika

VIRBAC Czech Republic, s.r.o.
Žitavského 496
156 00 Praha 5
Česká republika
Tel.: +420 608 836 529

Suomi/Finland

BIOFARM OY
Yrittäjätie 20
FI-03600 Karkkila
Puh/Tel: +358-9-225 2560
mikko.koivu@biofarm.fi

Κύπρος

ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.
13^ο χλμ Ε.Ο. Αθηνών - Λαμίας
EL-14452, Μεταμόρφωση
Τηλ.: +30 2106219520
info@virbac.gr

Latvija

OÜ ZOOVETVARU
Uusaru 5
EE-76505 Saue/Harjumaalgaunija
Tel: + 372 56480207
pv@zoovet.eu

Lietuva

OÜ ZOOVETVARU
Uusaru 5
EE-76505 Saue/Harjumaalgaunija
Estija
Tel: + 372 56480207
pv@zoovet.eu

România

Altius SA
Str. Zăgazului nr. 21-25, Corp A, et 8 si 8A
Ap. A.8.2, sect 1, cod 014261, București,
Romania
Tel: + 40 21 310 88 80

Sverige

VIRBAC Danmark A/S Filial Sverige
Box 1027
SE-171 21 Solna
Tel: +45 75521244
virbac@virbac.dk

United Kingdom (Northern Ireland)

VIRBAC IRELAND
McInerney & Saunders
38, Main Street
Swords, Co Dublin
K67E0A2
Republic Of Ireland
Tel: +44 (0)-1359 243243

Република България

САМ БС ЕООД
Бул. "Д-р Петър Дертлиев" 25, Търговски
център Лабиринт, ет. 5, офис САМ БС ЕООД
BG София 1335
Тел: +359 2 810 0173
sambs@sambs.bg

Hrvatska

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Francuska
Tel: 33 (0) 4 92 08 73 00

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

Benign prostatic hypertrophy (BPH) is a natural consequence of ageing. Over 80% of male dogs above 5 years of age are affected. BPH is a development and enlargement of the prostate due to the male hormone testosterone. This might lead to multiple non-specific clinical signs such as abdominal pain, difficulties in defaecation and urination, blood in urine and locomotive disorders.